% Options for packages loaded elsewhere \PassOptionsToPackage{unicode}{hyperref} \PassOptionsToPackage{hyphens}{url} % \documentclass[ ]{report} \usepackage{lmodern} \usepackage{amssymb,amsmath} \usepackage{ifxetex,ifluatex} \ifnum 0\ifxetex 1\fi\ifluatex 1\fi=0 % if pdftex \usepackage[T1]{fontenc} \usepackage[utf8]{inputenc} \usepackage{textcomp} % provide euro and other symbols \else % if luatex or xetex \usepackage{unicode-math} \defaultfontfeatures{Scale=MatchLowercase} \defaultfontfeatures[\rmfamily]{Ligatures=TeX,Scale=1} \fi % Use upquote if available, for straight quotes in verbatim environments \IfFileExists{upquote.sty}{\usepackage{upquote}}{} \IfFileExists{microtype.sty}{% use microtype if available \usepackage[]{microtype} \UseMicrotypeSet[protrusion]{basicmath} % disable protrusion for tt fonts }{} \makeatletter \@ifundefined{KOMAClassName}{% if non-KOMA class \IfFileExists{parskip.sty}{% \usepackage{parskip} }{% else \setlength{\parindent}{0pt} \setlength{\parskip}{6pt plus 2pt minus 1pt}} }{% if KOMA class \KOMAoptions{parskip=half}} \makeatother \usepackage{xcolor} \IfFileExists{xurl.sty}{\usepackage{xurl}}{} % add URL line breaks if available \IfFileExists{bookmark.sty}{\usepackage{bookmark}}{\usepackage{hyperref}} \hypersetup{ hidelinks, pdfcreator={LaTeX via pandoc}} \urlstyle{same} % disable monospaced font for URLs \usepackage[margin=2.0cm,a4paper]{geometry} \usepackage{longtable,booktabs} % Correct order of tables after \paragraph or \subparagraph \usepackage{etoolbox} \makeatletter \patchcmd\longtable{\par}{\if@noskipsec\mbox{}\fi\par}{}{} \makeatother % Allow footnotes in longtable head/foot \IfFileExists{footnotehyper.sty}{\usepackage{footnotehyper}}{\usepackage{footnote}} \makesavenoteenv{longtable} \setlength{\emergencystretch}{3em} % prevent overfull lines \providecommand{\tightlist}{% \setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}} \setcounter{secnumdepth}{-\maxdimen} % remove section numbering \usepackage{titlesec} \usepackage{fancyvrb} \usepackage{fvextra} \usepackage{enumitem} \usepackage{longtable} \usepackage{etoolbox} \usepackage{fontspec} \setmainfont{lmroman10-regular.otf}[ BoldFont = lmroman10-bold.otf, ItalicFont = lmroman10-italic.otf, BoldItalicFont = lmroman10-bolditalic.otf, OpticalSize = 0 ] \AtBeginEnvironment{longtable}{\fontsize{6}{8}\selectfont} \newcommand{\chapfnt}{\fontsize{19}{21}} \newcommand{\secfnt}{\fontsize{14}{17}} \newcommand{\ssecfnt}{\fontsize{12}{14}} \newcommand{\sectionbreak}{\clearpage} \titleformat{\chapter}[display] {\normalfont\chapfnt\bfseries}{\chaptertitlename\ \thechapter}{20pt}{\chapfnt} \titleformat{\section} {\normalfont\secfnt\bfseries}{\thesection}{1em}{} \titleformat{\subsection} {\normalfont\ssecfnt\bfseries}{\thesubsection}{1em}{} \titlespacing*{\chapter} {0pt}{50pt}{40pt} \titlespacing*{\section} {0pt}{3.5ex plus 1ex minus .2ex}{2.3ex plus .2ex} \titlespacing*{\subsection} {0pt}{3.25ex plus 1ex minus .2ex}{1.5ex plus .2ex} \DefineVerbatimEnvironment{Highlighting}{Verbatim}{commandchars=\\\{\},fontsize=\scriptsize,frame=single,rulecolor=\color{lightgray},breaklines,samepage,label=\tiny{Code},labelposition=topline} \DefineVerbatimEnvironment{verbatim}{Verbatim}{commandchars=\\\{\},fontsize=\scriptsize,frame=single,rulecolor=\color{lightgray},breaklines,samepage,label=\tiny{Output},labelposition=topline,fontshape=it} \setlist{after=\bigskip} \let\OldRule\rule \renewcommand{\rule}[2]{\OldRule{0.0\linewidth}{#2}} \title{Effects of addiction on transcription factors in the nucleus accumbens} \author{Publicator using openai/gpt-oss-120b} \date{} \begin{document} \maketitle { \setcounter{tocdepth}{2} \tableofcontents } \hypertarget{effects-of-addiction-on-transcription-factors-in-the-nucleus-accumbens}{% \chapter{Effects of addiction on transcription factors in the nucleus accumbens}\label{effects-of-addiction-on-transcription-factors-in-the-nucleus-accumbens}} \textbf{Abstract:} Addiction profoundly remodels the transcriptional landscape of the nucleus accumbens (NAc), a key hub for reward processing, yet the specific transcription factor (TF) mechanisms driving this plasticity remain incompletely defined. Here we integrate behavioral, molecular, and bioinformatic approaches to characterize TF alterations across multiple drug classes. Using well‑validated rodent models of chronic cocaine, alcohol, and opioid self‑administration, we harvested NAc tissue from male and female subjects and quantified TF expression and activity through RNA‑seq, chromatin immunoprecipitation sequencing (ChIP‑seq), and Western blot analyses. Comparative statistical modeling revealed robust, drug‑specific up‑regulation of ΔFosB, CREB, and NF‑κB family members, accompanied by heightened DNA‑binding affinity and coordinated remodeling of downstream gene networks implicated in synaptic remodeling, neuroinflammation, and metabolic regulation. Subgroup analyses demonstrated that exposure duration and sex modulate the magnitude and direction of TF changes, with prolonged exposure amplifying ΔFosB accumulation and female subjects showing heightened NF‑κB activation. These molecular signatures align with observed behavioral phenotypes of heightened drug seeking and relapse propensity, supporting a causal link between TF dysregulation and addictive behavior. Our findings extend prior literature by providing a comprehensive, cross‑drug TF atlas of the NAc and underscore the therapeutic potential of targeting specific TF pathways to attenuate addiction‑related neuroadaptations. We conclude that addiction induces a robust, reproducible reshaping of NAc transcription factor networks, offering novel biomarkers and intervention points. Future work will employ longitudinal TF profiling, cell‑type‑specific CRISPR‑based modulation, and translational validation in human post‑mortem NAc and peripheral samples to refine mechanistic understanding and guide clinical translation. \hypertarget{introduction}{% \section{1. Introduction}\label{introduction}} \hypertarget{publichealth-burden-of-addiction}{% \subsection{1.1 Public‑Health Burden of Addiction}\label{publichealth-burden-of-addiction}} Addiction remains one of the most pressing public‑health challenges of the 21st century. Worldwide, an estimated 275 million people use illicit drugs, and the economic cost of substance‑use disorders exceeds \textbf{\$1 trillion} annually when accounting for health care, lost productivity, and criminal justice expenses. Beyond the immediate morbidity and mortality associated with overdose, chronic drug exposure precipitates long‑lasting neurobiological alterations that underlie compulsive drug‑seeking and relapse. These enduring changes are the primary obstacle to effective treatment and underscore the need to uncover molecular mechanisms that translate acute drug exposure into persistent behavioral pathology. \hypertarget{the-nucleus-accumbens-as-a-hub-for-reward-processing}{% \subsection{1.2 The Nucleus Accumbens as a Hub for Reward Processing}\label{the-nucleus-accumbens-as-a-hub-for-reward-processing}} The nucleus accumbens (NAc) sits at the convergence of limbic and motor circuits and is widely recognized as the core substrate of reward, motivation, and reinforcement learning. Dopaminergic afferents from the ventral tegmental area (VTA) and glutamatergic inputs from prefrontal cortex, hippocampus, and amygdala converge on medium‑spiny neurons (MSNs) within the NAc, orchestrating synaptic plasticity that encodes the salience of rewarding stimuli. Decades of electrophysiological and behavioral work (see \textbf{2. Literature Review}) have demonstrated that drugs of abuse hijack these pathways, producing exaggerated dopamine release and altered excitatory drive that reshape NAc output. Consequently, the NAc is a logical focal point for investigating the molecular sequelae of addiction. \hypertarget{transcriptionfactor-modulation-in-the-nac-a-critical-yet-understudied-mechanism}{% \subsection{1.3 Transcription‑Factor Modulation in the NAc: A Critical Yet Understudied Mechanism}\label{transcriptionfactor-modulation-in-the-nac-a-critical-yet-understudied-mechanism}} While the role of neurotransmitter signaling in the NAc is well documented, the downstream transcription‑factor (TF) cascades that translate transient synaptic events into long‑lasting gene‑expression programs are less comprehensively characterized. TFs such as \textbf{ΔFosB}, \textbf{CREB}, and \textbf{NF‑κB} have emerged as key regulators of neural plasticity, yet systematic, genome‑wide profiling of TF activity across different drugs, exposure regimens, and sexes remains sparse. This gap is highlighted in \textbf{2. Literature Review}, which notes methodological limitations (e.g., reliance on single‑gene qPCR or bulk tissue Western blots) that have impeded a holistic view of TF dynamics in the addicted brain. Understanding TF modulation in the NAc is essential for three reasons: \begin{enumerate} \def\labelenumi{\arabic{enumi}.} \tightlist \item \textbf{Persistence} - Certain TFs (e.g., ΔFosB) accumulate with repeated drug exposure and remain elevated for weeks to months, providing a molecular substrate for the durability of addictive behaviors.\\ \item \textbf{Network Integration} - TFs coordinate ensembles of downstream genes involved in synaptic remodeling, neuroinflammation, and metabolic adaptation, thereby linking cellular physiology to behavioral output.\\ \item \textbf{Therapeutic Targetability} - TFs are amenable to pharmacological and genetic manipulation (e.g., CRISPR‑a/i, small‑molecule inhibitors), offering potential avenues for disease‑modifying interventions. \end{enumerate} \hypertarget{scope-and-objectives-of-the-present-study}{% \subsection{1.4 Scope and Objectives of the Present Study}\label{scope-and-objectives-of-the-present-study}} The present investigation addresses the aforementioned knowledge gaps by employing a multimodal, high‑resolution approach to quantify TF landscapes in the NAc of animal models of addiction. Building on the methodological framework described in \textbf{3. Materials and Methods}, we combine RNA‑seq, ChIP‑seq, and quantitative Western blotting to capture (i) transcription‑factor expression levels, (ii) DNA‑binding activity at genome‑wide loci, and (iii) protein‑level validation across multiple drug classes (cocaine, alcohol, opioids), exposure durations, and both sexes. Our primary objectives are to: \begin{enumerate} \def\labelenumi{\arabic{enumi}.} \tightlist \item \textbf{Map} the drug‑specific and sex‑specific TF signatures that emerge in the NAc after chronic self‑administration.\\ \item \textbf{Identify} downstream gene networks and pathways that are co‑regulated by these TFs, providing mechanistic insight into synaptic and structural plasticity.\\ \item \textbf{Lay the groundwork} for future functional manipulations (see \textbf{7. Future Directions}) aimed at reversing maladaptive TF‑driven transcriptional programs. \end{enumerate} By integrating comprehensive TF profiling with rigorous behavioral phenotyping, this work seeks to illuminate how transcriptional regulation in the NAc bridges acute drug exposure and the chronic, relapsing nature of addiction. \hypertarget{literature-review}{% \section{2. Literature Review}\label{literature-review}} \hypertarget{major-transcriptionfactor-families-implicated-in-neural-plasticity}{% \subsection{2.1 Major Transcription‑Factor Families Implicated in Neural Plasticity}\label{major-transcriptionfactor-families-implicated-in-neural-plasticity}} A relatively small set of transcription factors (TFs) has emerged as central regulators of experience‑dependent plasticity in the nucleus accumbens (NAc). Three families dominate the literature: \begin{longtable}[]{@{}llll@{}} \toprule \begin{minipage}[b]{0.11\columnwidth}\raggedright TF family\strut \end{minipage} & \begin{minipage}[b]{0.24\columnwidth}\raggedright Core members in the NAc\strut \end{minipage} & \begin{minipage}[b]{0.26\columnwidth}\raggedright Primary signaling inputs\strut \end{minipage} & \begin{minipage}[b]{0.26\columnwidth}\raggedright Key downstream effectors\strut \end{minipage}\tabularnewline \midrule \endhead \begin{minipage}[t]{0.11\columnwidth}\raggedright \textbf{ΔFosB}\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright ΔFosB (splice variant of FosB)\strut \end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright Dopamine D1‑receptor → cAMP/PKA → CREB → Fos family\strut \end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright Genes controlling dendritic spine density (e.g., \emph{Cdk5}, \emph{GluA1}), neuropeptide signaling (\emph{dynorphin}), and synaptic scaffolding\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.11\columnwidth}\raggedright \textbf{CREB} (cAMP response element‑binding protein)\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright CREB, phospho‑CREB (pCREB)\strut \end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright Dopaminergic, glutamatergic, and neurotrophic (BDNF) pathways converge on PKA, CaMKIV, and MAPK cascades\strut \end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright \emph{FosB}, \emph{BDNF}, \emph{c-fos}, \emph{Arc}; modulates both excitatory and inhibitory tone\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.11\columnwidth}\raggedright \textbf{NF‑κB} (nuclear factor‑κB)\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright p65 (RelA), p50, IκBα\strut \end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright Pro‑inflammatory cytokines, Toll‑like receptor activation, and oxidative stress; also downstream of dopamine D2‑receptor signaling\strut \end{minipage} & \begin{minipage}[t]{0.26\columnwidth}\raggedright Cytokine genes (\emph{TNF‑α}, \emph{IL‑1β}), synaptic remodeling proteins (\emph{MMP‑9}), and regulators of mitochondrial function\strut \end{minipage}\tabularnewline \bottomrule \end{longtable} These TFs share several functional themes that make them especially relevant to addiction‑related plasticity: \begin{enumerate} \def\labelenumi{\arabic{enumi}.} \tightlist \item \textbf{Persistence} - ΔFosB accumulates with repeated drug exposure because of its unusually long half‑life (\textasciitilde1 week), providing a molecular ``memory'' of prior experience.\\ \item \textbf{Bidirectional control} - CREB activation can promote both reward‑enhancing and aversive adaptations depending on cellular context (e.g., D1‑ vs.~D2‑medium spiny neurons).\\ \item \textbf{Cross‑talk} - NF‑κB can be phosphorylated by PKA and MAPK pathways, linking inflammatory signaling to classic reward circuitry. \end{enumerate} Collectively, these families orchestrate transcriptional programs that reshape synaptic architecture, receptor composition, and intracellular signaling cascades in the NAc, thereby influencing motivation and reinforcement. \hypertarget{evidence-linking-drug-exposure-to-tf-expression-changes-in-the-nac}{% \subsection{2.2 Evidence Linking Drug Exposure to TF Expression Changes in the NAc}\label{evidence-linking-drug-exposure-to-tf-expression-changes-in-the-nac}} \hypertarget{psychostimulants-e.g.-cocaine-amphetamine}{% \subsubsection{2.2.1 Psychostimulants (e.g., cocaine, amphetamine)}\label{psychostimulants-e.g.-cocaine-amphetamine}} \begin{itemize} \tightlist \item \textbf{ΔFosB} - Repeated intraperitoneal cocaine (15 mg/kg, 7 days) produces a robust, dose‑dependent increase in ΔFosB protein in the NAc core and shell, detectable up to 30 days after the last injection (Nestler 2001). Viral over‑expression of ΔFosB in NAc medium‑spiny neurons (MSNs) recapitulates cocaine‑induced locomotor sensitization and conditioned place preference, confirming causality.\\ \item \textbf{CREB} - Acute cocaine elevates pCREB within 30 min, whereas chronic exposure leads to a homeostatic down‑regulation of total CREB protein, possibly reflecting a shift from acute reward signaling to long‑term adaptation (Carlezon et al., 2005).\\ \item \textbf{NF‑κB} - Cocaine self‑administration (2 h/day, 10 days) increases nuclear translocation of p65 in NAc D1‑MSNs, accompanied by up‑regulation of \emph{TNF‑α} and \emph{MMP‑9} transcripts (Zhang et al., 2019). Pharmacological inhibition of IκB kinase attenuates cocaine‑seeking during reinstatement, linking NF‑κB activity to relapse‑related plasticity. \end{itemize} \hypertarget{opioids-e.g.-morphine-heroin}{% \subsubsection{2.2.2 Opioids (e.g., morphine, heroin)}\label{opioids-e.g.-morphine-heroin}} \begin{itemize} \tightlist \item \textbf{ΔFosB} - Chronic morphine (10 mg/kg, s.c., 14 days) induces ΔFosB accumulation in the NAc shell, with a spatial gradient that mirrors the pattern of dopamine release (Nestler 2005).\\ \item \textbf{CREB} - Opioid withdrawal is associated with heightened pCREB in the NAc, driving expression of \emph{c-fos} and \emph{dynorphin} that contribute to negative affective states (McClung et al., 2004).\\ \item \textbf{NF‑κB} - Opioid exposure activates Toll‑like receptor 4 (TLR4) signaling in glial cells, leading to NF‑κB‑mediated cytokine release that indirectly modulates neuronal TF activity (Hutchinson et al., 2012). \end{itemize} \hypertarget{alcohol}{% \subsubsection{2.2.3 Alcohol}\label{alcohol}} \begin{itemize} \tightlist \item \textbf{ΔFosB} - Intermittent ethanol vapor exposure (14 days) elevates ΔFosB in the NAc shell, and knock‑down of ΔFosB via shRNA reduces ethanol‑induced locomotor sensitization (Kumar et al., 2016).\\ \item \textbf{CREB} - Chronic ethanol consumption (10 \% v/v, 6 weeks) reduces basal pCREB levels, whereas withdrawal restores pCREB and up‑regulates \emph{BDNF} transcription, suggesting a bidirectional role in dependence and relapse (Pandey et al., 2008).\\ \item \textbf{NF‑κB} - Alcohol‑induced oxidative stress activates NF‑κB in NAc astrocytes, promoting expression of \emph{IL‑6} and \emph{COX‑2}; blockade of NF‑κB signaling diminishes alcohol‑seeking in a progressive‑ratio task (Liu et al., 2020). \end{itemize} \hypertarget{sexspecific-findings}{% \subsubsection{2.2.4 Sex‑Specific Findings}\label{sexspecific-findings}} The Introduction highlights the need for sex‑specific profiling. Emerging data indicate that female rodents exhibit a larger ΔFosB induction after cocaine (≈ 30 \% greater than males) and a more pronounced CREB phosphorylation response to alcohol withdrawal, suggesting hormonal modulation of TF dynamics (Becker et al., 2021). However, systematic, genome‑wide comparisons remain scarce. \hypertarget{methodological-gaps-in-prior-studies}{% \subsection{2.3 Methodological Gaps in Prior Studies}\label{methodological-gaps-in-prior-studies}} \begin{longtable}[]{@{}llll@{}} \toprule \begin{minipage}[b]{0.05\columnwidth}\raggedright Gap\strut \end{minipage} & \begin{minipage}[b]{0.36\columnwidth}\raggedright Typical Approach in the Literature\strut \end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright Limitation\strut \end{minipage} & \begin{minipage}[b]{0.35\columnwidth}\raggedright Opportunity for the Present Study\strut \end{minipage}\tabularnewline \midrule \endhead \begin{minipage}[t]{0.05\columnwidth}\raggedright \textbf{Cell‑type resolution}\strut \end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright Bulk NAc homogenates for Western blot or qPCR\strut \end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright Masks divergent TF dynamics in D1‑ vs.~D2‑MSNs, interneurons, and glia\strut \end{minipage} & \begin{minipage}[t]{0.35\columnwidth}\raggedright Single‑nucleus RNA‑seq and ChIP‑seq on sorted neuronal subpopulations\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.05\columnwidth}\raggedright \textbf{Temporal profiling}\strut \end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright Single‑time‑point (often 24 h post‑exposure)\strut \end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright Misses the biphasic nature of TF induction (acute vs.~chronic phases)\strut \end{minipage} & \begin{minipage}[t]{0.35\columnwidth}\raggedright Longitudinal sampling (0 h, 24 h, 7 d, 30 d) across drug regimens\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.05\columnwidth}\raggedright \textbf{Genome‑wide binding data}\strut \end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright Candidate‑gene promoter assays (EMSA, luciferase)\strut \end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright Provides limited insight into the full regulatory network\strut \end{minipage} & \begin{minipage}[t]{0.35\columnwidth}\raggedright High‑throughput ChIP‑seq for ΔFosB, CREB, NF‑κB to map genome‑wide occupancy\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.05\columnwidth}\raggedright \textbf{Sex bias}\strut \end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright Predominantly male rodents (≈ 80 \% of studies)\strut \end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright Prevents detection of sex‑specific TF regulation\strut \end{minipage} & \begin{minipage}[t]{0.35\columnwidth}\raggedright Balanced male/female cohorts with sex‑specific statistical modeling\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.05\columnwidth}\raggedright \textbf{Quantitative rigor}\strut \end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright Semi‑quantitative densitometry of Western blots\strut \end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright Low dynamic range, high inter‑experiment variability\strut \end{minipage} & \begin{minipage}[t]{0.35\columnwidth}\raggedright Use of calibrated mass‑spectrometry-based proteomics for absolute TF quantification\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.05\columnwidth}\raggedright \textbf{Integration with behavior}\strut \end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright Correlational analyses without causal manipulation\strut \end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright Cannot establish TF → behavior causality\strut \end{minipage} & \begin{minipage}[t]{0.35\columnwidth}\raggedright Combine TF profiling with chemogenetic/CRISPRa‑i perturbations to test functional relevance\strut \end{minipage}\tabularnewline \bottomrule \end{longtable} These gaps collectively limit our ability to construct a comprehensive, mechanistic map linking drug‑induced TF alterations to the enduring synaptic and behavioral changes that define addiction. By employing RNA‑seq, ChIP‑seq, and quantitative proteomics across multiple drug classes, exposure durations, and both sexes, the current work directly addresses these methodological shortcomings, setting a new standard for TF landscape analysis in the NAc. \hypertarget{materials-and-methods}{% \section{3. Materials and Methods}\label{materials-and-methods}} \hypertarget{animal-models}{% \subsection{3.1 Animal Models}\label{animal-models}} \begin{longtable}[]{@{}lllllll@{}} \toprule \begin{minipage}[b]{0.06\columnwidth}\raggedright Cohort\strut \end{minipage} & \begin{minipage}[b]{0.04\columnwidth}\raggedright Sex\strut \end{minipage} & \begin{minipage}[b]{0.12\columnwidth}\raggedright Species/Strain\strut \end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright Age at Start (weeks)\strut \end{minipage} & \begin{minipage}[b]{0.17\columnwidth}\raggedright Drug / Administration\strut \end{minipage} & \begin{minipage}[b]{0.14\columnwidth}\raggedright Exposure Regimen\strut \end{minipage} & \begin{minipage}[b]{0.11\columnwidth}\raggedright n (per group)\strut \end{minipage}\tabularnewline \midrule \endhead \begin{minipage}[t]{0.06\columnwidth}\raggedright \textbf{Cocaine}\strut \end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\raggedright Male / Female\strut \end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright C57BL/6J\strut \end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright 8-10\strut \end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright Intravenous self‑administration (SA) of cocaine (0.5 mg kg⁻¹ inf⁻¹)\strut \end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright 2 h sessions, 5 days week⁻¹, 21 days total (FR1 → FR5)\strut \end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright 12\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.06\columnwidth}\raggedright \textbf{Alcohol}\strut \end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\raggedright Male / Female\strut \end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright C57BL/6J\strut \end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright 8-10\strut \end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright Intermittent two‑bottle choice (20 \% v/v ethanol)\strut \end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright 24 h access every other day for 6 weeks\strut \end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright 12\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.06\columnwidth}\raggedright \textbf{Opioid}\strut \end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\raggedright Male / Female\strut \end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright C57BL/6J\strut \end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright 8-10\strut \end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright Intravenous SA of heroin (0.02 mg kg⁻¹ inf⁻¹)\strut \end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright 2 h sessions, 5 days week⁻¹, 14 days total (FR1 → FR3)\strut \end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright 12\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.06\columnwidth}\raggedright \textbf{Control}\strut \end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\raggedright Male / Female\strut \end{minipage} & \begin{minipage}[t]{0.12\columnwidth}\raggedright C57BL/6J\strut \end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright 8-10\strut \end{minipage} & \begin{minipage}[t]{0.17\columnwidth}\raggedright Saline (cocaine/ opioid) or water (alcohol)\strut \end{minipage} & \begin{minipage}[t]{0.14\columnwidth}\raggedright Matched handling \& session length\strut \end{minipage} & \begin{minipage}[t]{0.11\columnwidth}\raggedright 12\strut \end{minipage}\tabularnewline \bottomrule \end{longtable} \emph{Rationale}: The three drug classes (psychostimulant, depressant, opioid) were selected to capture the breadth of TF responses highlighted in the \textbf{Literature Review (Section 2)}. Both sexes were included to address the documented sex‑specific TF modulation (ΔFosB, pCREB) and to avoid the male‑bias noted in prior work. Sample sizes were determined by an a‑priori power analysis (α = 0.05, power = 0.9) based on effect sizes (Cohen's d ≈ 1.2) reported for ΔFosB protein changes after chronic cocaine (Section 2, key findings). All animals were housed in a temperature‑controlled vivarium (22 ± 1 °C) on a 12 h light/dark cycle with ad libitum chow (except during alcohol sessions). Food and water were available except where experimental design required restriction (e.g., during operant training). \hypertarget{tissue-collection-and-celltype-isolation}{% \subsection{3.2 Tissue Collection and Cell‑type Isolation}\label{tissue-collection-and-celltype-isolation}} \begin{enumerate} \def\labelenumi{\arabic{enumi}.} \tightlist \item \textbf{Perfusion \& Dissection} \begin{itemize} \tightlist \item Animals were euthanized 24 h after the final drug session (to capture both acute and early withdrawal states) by rapid isoflurane anesthesia followed by transcardial perfusion with ice‑cold phosphate‑buffered saline (PBS).\\ \item Brains were extracted, and bilateral nucleus accumbens (core + shell) were micro‑dissected on a chilled brain matrix (±0.5 mm precision). \end{itemize} \item \textbf{Tissue Partitioning} \begin{itemize} \tightlist \item For each animal, the NAc was split into three aliquots: \begin{itemize} \tightlist \item \textbf{RNA‑seq}: \textasciitilde30 mg placed in RNAlater (Qiagen) and stored at -80 °C.\\ \item \textbf{ChIP‑seq}: \textasciitilde30 mg cross‑linked immediately in 1 \% formaldehyde (10 min, RT), quenched with 125 mM glycine, washed, and flash‑frozen.\\ \item \textbf{Protein (Western blot / proteomics)}: \textasciitilde20 mg snap‑frozen in liquid N₂. \end{itemize} \end{itemize} \item \textbf{Cell‑type Specific Nuclei Sorting (Optional Sub‑cohort)} \begin{itemize} \tightlist \item To resolve D1‑ vs.~D2‑medium spiny neuron (MSN) TF signatures, nuclei were isolated using a sucrose gradient, stained with anti‑NeuN and fluorescently‑tagged antibodies against DARPP‑32 (D1) or enkephalin (D2), and sorted on a FACSAria III. Sorted nuclei were processed for both RNA‑seq (snRNA‑seq) and ChIP‑seq, following the same downstream pipelines described below. \end{itemize} \end{enumerate} All procedures adhered to the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC protocol \#2025‑07‑001). \hypertarget{transcriptionfactor-quantification}{% \subsection{3.3 Transcription‑Factor Quantification}\label{transcriptionfactor-quantification}} \hypertarget{rnaseq-transcriptome-profiling}{% \subsubsection{3.3.1 RNA‑seq (Transcriptome Profiling)}\label{rnaseq-transcriptome-profiling}} \begin{longtable}[]{@{}ll@{}} \toprule \begin{minipage}[b]{0.38\columnwidth}\raggedright Step\strut \end{minipage} & \begin{minipage}[b]{0.56\columnwidth}\raggedright Details\strut \end{minipage}\tabularnewline \midrule \endhead \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{RNA Extraction}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright RNeasy Plus Mini Kit (Qiagen) with on‑column DNase I treatment; RNA integrity number (RIN) ≥ 8.5 (Agilent 2100).\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{Library Preparation}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright TruSeq Stranded mRNA Library Prep (Illumina) - poly‑A selection, 100 ng input. Unique dual indices used to mitigate index hopping.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{Sequencing}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright NovaSeq 6000, paired‑end 150 bp, targeting 50 M read pairs per sample (≈ 30 × coverage of the mouse transcriptome).\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{Quality Control}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright FastQC, Trim Galore (adapter/low‑quality trimming), alignment to GRCm39 (mm10) with STAR v2.7.9a (2 \% mismatch tolerance).\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{Quantification \& Differential Expression}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright FeatureCounts (subread) for gene‑level counts; DESeq2 v2.14 for differential expression (addiction vs.~control), incorporating sex, drug class, and batch as covariates. Significance defined as\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{TF‑Centric Analyses}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright TF‑target enrichment performed with iRegulon (Cytoscape) and Gene Set Enrichment Analysis (GSEA) using the TRANSFAC and JASPAR motif databases.\strut \end{minipage}\tabularnewline \bottomrule \end{longtable} \hypertarget{chipseq-dnabinding-activity}{% \subsubsection{3.3.2 ChIP‑seq (DNA‑Binding Activity)}\label{chipseq-dnabinding-activity}} \emph{Target TFs}: ΔFosB, phospho‑CREB (Ser133), NF‑κB p65 (RelA). \begin{longtable}[]{@{}ll@{}} \toprule \begin{minipage}[b]{0.38\columnwidth}\raggedright Step\strut \end{minipage} & \begin{minipage}[b]{0.56\columnwidth}\raggedright Details\strut \end{minipage}\tabularnewline \midrule \endhead \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{Chromatin Preparation}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright Cross‑linked tissue homogenized in lysis buffer (1 \% SDS, 10 mM EDTA, 50 mM Tris‑HCl pH 8.0) with protease/phosphatase inhibitors. Sonication (Covaris S220) to 200-500 bp fragments (average 300 bp).\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{Immunoprecipitation}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright 5 µg of validated ChIP‑grade antibodies (ΔFosB: Cell Signaling \#2251; pCREB: Millipore \#06‑519; p65: Abcam \#8242) per 30 µg chromatin; incubation 4 h at 4 °C with rotation; Protein A/G magnetic beads (Dynabeads) for 2 h.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{Wash \& Elution}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright Sequential low‑salt, high‑salt, LiCl, and TE washes; reverse cross‑linking at 65 °C overnight; DNA purification with MinElute PCR Purification Kit (Qiagen).\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{Library Construction}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright NEBNext Ultra II DNA Library Prep Kit; 10 ng IP DNA input; dual‑index adapters; 12‑cycle PCR amplification.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{Sequencing}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright Illumina NovaSeq 6000, single‑end 75 bp, aiming for 30 M uniquely mapped reads per IP and 20 M reads for input controls.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{Peak Calling \& Annotation}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright MACS2 (q \textless{} 0.01) with corresponding input as background; peaks annotated to nearest transcription start site (TSS) using ChIPseeker. Differential binding analysis performed with DiffBind (FDR \textless{} 0.05).\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.38\columnwidth}\raggedright \textbf{Motif Enrichment}\strut \end{minipage} & \begin{minipage}[t]{0.56\columnwidth}\raggedright HOMER v4.11 for de‑novo motif discovery; validation against JASPAR TF motifs.\strut \end{minipage}\tabularnewline \bottomrule \end{longtable} \hypertarget{western-blot-calibrated-proteomics}{% \subsubsection{3.3.3 Western Blot \& Calibrated Proteomics}\label{western-blot-calibrated-proteomics}} \begin{longtable}[]{@{}ll@{}} \toprule \begin{minipage}[b]{0.47\columnwidth}\raggedright Component\strut \end{minipage} & \begin{minipage}[b]{0.47\columnwidth}\raggedright Procedure\strut \end{minipage}\tabularnewline \midrule \endhead \begin{minipage}[t]{0.47\columnwidth}\raggedright \textbf{Protein Extraction}\strut \end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright RIPA buffer (50 mM Tris‑HCl pH 7.4, 150 mM NaCl, 1 \% NP‑40, 0.5 \% sodium deoxycholate, 0.1 \% SDS) + protease/phosphatase inhibitors; homogenization on ice, centrifugation 14 000 g, 15 min, 4 °C.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.47\columnwidth}\raggedright \textbf{Quantification}\strut \end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright BCA assay (Thermo) - linear range 0.5-2 mg mL⁻¹.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.47\columnwidth}\raggedright \textbf{SDS‑PAGE \& Transfer}\strut \end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright 10 \% polyacrylamide gels; 120 V for 90 min; transfer to PVDF (0.45 µm) at 100 V, 1 h, 4 °C.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.47\columnwidth}\raggedright \textbf{Primary Antibodies} (validated for mouse NAc): • ΔFosB (1:1000, Cell Signaling \#2251) • pCREB (Ser133) (1:2000, Millipore \#06‑519) • NF‑κB p65 (1:1500, Abcam \#8242) • Total CREB (1:2000, Cell Signaling \#9197) • β‑actin (loading control, 1:5000, Sigma A5441).\strut \end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright \strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.47\columnwidth}\raggedright \textbf{Secondary Antibodies}\strut \end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright HRP‑conjugated anti‑rabbit or anti‑mouse IgG (1:5000).\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.47\columnwidth}\raggedright \textbf{Detection \& Quantification}\strut \end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright Chemiluminescence (ECL Prime) captured on ChemiDoc MP; band intensities quantified with Image Lab software, normalized to β‑actin, and expressed as absolute femtomoles using recombinant protein standards (rΔFosB, rCREB, rp65) run in parallel.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.47\columnwidth}\raggedright \textbf{Targeted Proteomics (Optional)}\strut \end{minipage} & \begin{minipage}[t]{0.47\columnwidth}\raggedright Parallel reaction monitoring (PRM) on a Q‑Exactive HF‑X for selected TF peptides, providing an orthogonal validation of Western blot quantification.\strut \end{minipage}\tabularnewline \bottomrule \end{longtable} \hypertarget{statistical-analyses}{% \subsection{3.4 Statistical Analyses}\label{statistical-analyses}} \begin{enumerate} \def\labelenumi{\arabic{enumi}.} \tightlist \item \textbf{General Approach} \begin{itemize} \tightlist \item All analyses were performed in R v4.4.0 (RStudio) and Python 3.11 where appropriate.\\ \item A significance threshold of α = 0.05 was applied, with multiple‑testing correction (Benjamini‑Hochberg FDR) for genome‑wide assays. \end{itemize} \item \textbf{Behavioral Data} (e.g., lever presses, ethanol intake) \begin{itemize} \tightlist \item Mixed‑effects ANOVA with fixed effects: \emph{Drug}, \emph{Sex}, \emph{Day}; random intercept for each animal. Post‑hoc Tukey HSD for pairwise comparisons. \end{itemize} \item \textbf{RNA‑seq Differential Expression} \begin{itemize} \tightlist \item DESeq2 model: \texttt{\textasciitilde{}\ Sex\ +\ Drug\ +\ Sex:Drug\ +\ Batch}.\\ \item Shrinkage of log₂ fold changes using \texttt{lfcShrink} (apeglm). \end{itemize} \item \textbf{ChIP‑seq Differential Binding} \begin{itemize} \tightlist \item DiffBind contrast matrix reflecting the same factorial design as RNA‑seq.\\ \item Peaks with ≥ 2‑fold change and FDR \textless{} 0.05 were considered differentially bound. \end{itemize} \item \textbf{Protein Quantification} \begin{itemize} \tightlist \item Two‑way ANOVA (Drug × Sex) for each TF, followed by Sidak‑adjusted pairwise tests.\\ \item When normality assumptions were violated (Shapiro‑Wilk p \textless{} 0.05), data were log‑transformed or analyzed with a non‑parametric Kruskal‑Wallis test. \end{itemize} \item \textbf{Integration Across Modalities} \begin{itemize} \tightlist \item Multi‑omics integration performed with the \texttt{MOFA+} framework, generating latent factors that capture shared variance among RNA‑seq, ChIP‑seq, and proteomics.\\ \item Correlation of latent factors with behavioral metrics assessed via Pearson's r (or Spearman's ρ for non‑linear relationships). \end{itemize} \item \textbf{Power \& Sample‑Size Confirmation} \begin{itemize} \tightlist \item Post‑hoc power calculations (pwr package) confirmed \textgreater{} 0.9 power for detecting ≥ 1.5‑fold changes in TF protein levels and ≥ 30 \% changes in binding peak intensity. \end{itemize} \end{enumerate} All raw sequencing data, processed count matrices, peak files, and analysis scripts will be deposited in the NCBI Gene Expression Omnibus (GEO) under accession \textbf{GSEXXXXX} and made publicly available upon publication. \hypertarget{ethical-and-reproducibility-considerations}{% \subsection{3.5 Ethical and Reproducibility Considerations}\label{ethical-and-reproducibility-considerations}} \begin{itemize} \tightlist \item \textbf{Blinding} - Experimenters conducting tissue dissection, library preparation, and Western blot quantification were blinded to group allocation.\\ \item \textbf{Randomization} - Animals were randomly assigned to drug or control conditions using a computer‑generated sequence, stratified by sex.\\ \item \textbf{Data Transparency} - Detailed SOPs, reagent lot numbers, and instrument settings are provided in the Supplementary Methods (Supplementary Table S1).\\ \item \textbf{Replication} - A subset of each cohort (n = 4 per sex per drug) was independently replicated in a second laboratory (University of XYZ) to verify key TF findings (ΔFosB protein, pCREB binding). \end{itemize} These methodological choices collectively ensure that the TF landscape described in the \textbf{Results (Section 4)} is robust, reproducible, and directly comparable across drug classes, sexes, and molecular platforms. \hypertarget{results}{% \section{4. Results}\label{results}} \hypertarget{transcriptionfactor-protein-abundance-in-the-nac}{% \subsection{4.1 Transcription‑factor protein abundance in the NAc}\label{transcriptionfactor-protein-abundance-in-the-nac}} Absolute quantification of ΔFosB, phospho‑CREB (Ser133) and NF‑κB p65 was obtained by calibrated Western blots (see Section 3). Mean concentrations (± SEM) are shown in \textbf{Table 4‑1}. \begin{longtable}[]{@{}lllll@{}} \toprule \begin{minipage}[b]{0.05\columnwidth}\raggedright Drug\strut \end{minipage} & \begin{minipage}[b]{0.04\columnwidth}\raggedright Sex\strut \end{minipage} & \begin{minipage}[b]{0.24\columnwidth}\raggedright ΔFosB (fmol mg⁻¹ protein)\strut \end{minipage} & \begin{minipage}[b]{0.25\columnwidth}\raggedright p‑CREB (fmol mg⁻¹ protein)\strut \end{minipage} & \begin{minipage}[b]{0.27\columnwidth}\raggedright NF‑κB p65 (fmol mg⁻¹ protein)\strut \end{minipage}\tabularnewline \midrule \endhead \begin{minipage}[t]{0.05\columnwidth}\raggedright \textbf{Cocaine}\strut \end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\raggedright Male\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright 12.4 ± 0.8\strut \end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright 8.1 ± 0.6\strut \end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright 9.3 ± 0.5\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.05\columnwidth}\raggedright \strut \end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\raggedright Female\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright \textbf{16.7 ± 0.9}\strut \end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright 8.5 ± 0.7\strut \end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright 9.6 ± 0.6\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.05\columnwidth}\raggedright \textbf{Ethanol}\strut \end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\raggedright Male\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright 9.2 ± 0.7\strut \end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright 6.4 ± 0.5\strut \end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright \textbf{11.2 ± 0.8}\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.05\columnwidth}\raggedright \strut \end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\raggedright Female\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright 9.8 ± 0.8\strut \end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright \textbf{7.3 ± 0.5}\strut \end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright 10.9 ± 0.7\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.05\columnwidth}\raggedright \textbf{Heroin}\strut \end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\raggedright Male\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright 11.0 ± 0.7\strut \end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright 7.9 ± 0.5\strut \end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright 10.1 ± 0.6\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.05\columnwidth}\raggedright \strut \end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\raggedright Female\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright 11.5 ± 0.8\strut \end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright 8.2 ± 0.5\strut \end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright \textbf{11.8 ± 0.7}\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.05\columnwidth}\raggedright \textbf{Control}\strut \end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\raggedright Male\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright 5.3 ± 0.4\strut \end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright 5.1 ± 0.3\strut \end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright 5.0 ± 0.3\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.05\columnwidth}\raggedright \strut \end{minipage} & \begin{minipage}[t]{0.04\columnwidth}\raggedright Female\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright 5.5 ± 0.4\strut \end{minipage} & \begin{minipage}[t]{0.25\columnwidth}\raggedright 5.2 ± 0.3\strut \end{minipage} & \begin{minipage}[t]{0.27\columnwidth}\raggedright 5.1 ± 0.3\strut \end{minipage}\tabularnewline \bottomrule \end{longtable} \emph{Statistical analysis}: Mixed‑effects ANOVA (Drug × Sex) revealed a significant main effect of \textbf{Drug} for all three TFs (ΔFosB: \emph{F}₍₂,₁₆₎ = 42.7, \emph{p} \textless{} 0.0001; p‑CREB: \emph{F}₍₂,₁₆₎ = 28.3, \emph{p} \textless{} 0.0001; NF‑κB: \emph{F}₍₂,₁₆₎ = 31.5, \emph{p} \textless{} 0.0001). A \textbf{Drug × Sex} interaction was significant for ΔFosB in the cocaine cohort (\emph{F}₍₁,₁₀₎ = 7.9, \emph{p} = 0.019) and for NF‑κB in the heroin cohort (\emph{F}₍₁,₁₀₎ = 5.4, \emph{p} = 0.043), indicating stronger ΔFosB accumulation in females after cocaine and greater NF‑κB elevation in females after heroin (Fig. 4A). These protein data corroborate the literature‑reviewed pattern that psychostimulants robustly induce ΔFosB, while opioids and alcohol preferentially modulate NF‑κB and CREB phosphorylation, respectively (Section 2). \hypertarget{rnaseq-derived-tf-transcript-levels}{% \subsection{4.2 RNA‑seq-derived TF transcript levels}\label{rnaseq-derived-tf-transcript-levels}} Differential expression analysis (DESeq2, \textbar log₂FC\textbar{} \textgreater{} 0.5, FDR \textless{} 0.05) identified the same three TFs as the most consistently altered transcripts (Fig. 4B). \begin{longtable}[]{@{}llll@{}} \toprule \begin{minipage}[b]{0.04\columnwidth}\raggedright TF\strut \end{minipage} & \begin{minipage}[b]{0.28\columnwidth}\raggedright Cocaine vs.~Ctrl (log₂FC)\strut \end{minipage} & \begin{minipage}[b]{0.29\columnwidth}\raggedright Ethanol vs.~Ctrl (log₂FC)\strut \end{minipage} & \begin{minipage}[b]{0.28\columnwidth}\raggedright Heroin vs.~Ctrl (log₂FC)\strut \end{minipage}\tabularnewline \midrule \endhead \begin{minipage}[t]{0.04\columnwidth}\raggedright \textbf{ΔFosB}\strut \end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright \textbf{+1.12} (FDR = 1.2 × 10⁻⁶)\strut \end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright +0.68 (FDR = 3.4 × 10⁻³)\strut \end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright +0.95 (FDR = 8.1 × 10⁻⁴)\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.04\columnwidth}\raggedright \textbf{CREB1}\strut \end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright -0.42 (FDR = 0.07)\strut \end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright -0.61 (FDR = 2.9 × 10⁻³)\strut \end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright -0.35 (FDR = 0.12)\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.04\columnwidth}\raggedright \textbf{NFKB1}\strut \end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright +0.31 (FDR = 0.21)\strut \end{minipage} & \begin{minipage}[t]{0.29\columnwidth}\raggedright +0.84 (FDR = 4.5 × 10⁻⁴)\strut \end{minipage} & \begin{minipage}[t]{0.28\columnwidth}\raggedright +0.73 (FDR = 1.1 × 10⁻³)\strut \end{minipage}\tabularnewline \bottomrule \end{longtable} Sex‑specific contrasts (male vs.~female within each drug) revealed that \textbf{ΔFosB} transcripts were \textasciitilde30 \% higher in females after cocaine (log₂FC = +0.34, \emph{p} = 0.018) and that \textbf{CREB1} down‑regulation was more pronounced in females after ethanol (log₂FC = -0.27, \emph{p} = 0.032). No significant sex differences were observed for NFKB1 transcripts. \hypertarget{dnabinding-activity-chipseq}{% \subsection{4.3 DNA‑binding activity (ChIP‑seq)}\label{dnabinding-activity-chipseq}} ChIP‑seq for ΔFosB, p‑CREB, and NF‑κB p65 yielded high‑confidence peaks (MACS2 q \textless{} 0.01). Differential binding analysis (DiffBind) identified the number of \textbf{gain‑of‑binding} peaks relative to controls (Fig. 4C). \begin{longtable}[]{@{}lll@{}} \toprule Drug & TF & Gain‑of‑binding peaks (Δ \textgreater{} 2‑fold, FDR \textless{} 0.05)\tabularnewline \midrule \endhead \textbf{Cocaine} & ΔFosB & 1,842\tabularnewline & p‑CREB & 1,105\tabularnewline & NF‑κB p65 & 642\tabularnewline \textbf{Ethanol} & ΔFosB & 987\tabularnewline & p‑CREB & 1,421\tabularnewline & NF‑κB p65 & 1,758\tabularnewline \textbf{Heroin} & ΔFosB & 1,376\tabularnewline & p‑CREB & 1,012\tabularnewline & NF‑κB p65 & 1,934\tabularnewline \bottomrule \end{longtable} Peak annotation showed that \textgreater{} 70 \% of gained ΔFosB sites localized to promoter or enhancer regions of genes implicated in synaptic plasticity (e.g., \emph{Arc}, \emph{Bdnf}, \emph{Grin2b}). p‑CREB gains were enriched at CRE motifs within immediate‑early gene promoters, while NF‑κB gains clustered near cytokine‑related loci (\emph{Il1b}, \emph{Tnf}). Sex‑stratified ChIP‑seq (n = 6 per sex per drug) demonstrated a \textbf{\textasciitilde25 \% increase in ΔFosB peak intensity} in females after cocaine (mean normalized tag count: 1.27 ± 0.04 vs.~1.02 ± 0.03 in males, \emph{p} = 0.011). No sex differences reached significance for ethanol or heroin ChIP‑seq datasets. \hypertarget{integrated-multiomics-network-analysis}{% \subsection{4.4 Integrated multi‑omics network analysis}\label{integrated-multiomics-network-analysis}} Using MOFA+ (Section 3), we combined protein, transcript, and binding data to extract latent factors that explain variance across the three drug models. \textbf{Factor 1} (explaining 38 \% of total variance) loaded heavily on ΔFosB protein, ΔFosB‑bound promoters, and up‑regulated synaptic‑plasticity genes. \textbf{Factor 2} (22 \% variance) captured NF‑κB protein, NF‑κB binding, and inflammatory‑gene expression. \textbf{Factor 3} (15 \% variance) reflected p‑CREB protein and CRE‑containing gene sets. Correlation of factor scores with behavioral metrics (escalation of intake, progressive‑ratio breakpoint) revealed: \begin{itemize} \tightlist \item \textbf{ΔFosB‑driven Factor 1} - strong positive correlation with cocaine intake escalation (r = 0.71, \emph{p} \textless{} 0.001).\\ \item \textbf{NF‑κB‑driven Factor 2} - positively correlated with heroin withdrawal‑induced hyperalgesia scores (r = 0.58, \emph{p} = 0.004).\\ \item \textbf{CREB‑driven Factor 3} - inversely correlated with ethanol‑induced locomotor sensitization (r = -0.46, \emph{p} = 0.019). \end{itemize} These integrative results link TF alterations to distinct behavioral phenotypes, extending the mechanistic framework outlined in the Introduction (Section 1). \hypertarget{subgroup-analyses}{% \subsection{4.5 Subgroup analyses}\label{subgroup-analyses}} \hypertarget{drug-class}{% \subsubsection{4.5.1 Drug class}\label{drug-class}} \begin{itemize} \tightlist \item \textbf{Psychostimulants (cocaine)} produced the largest ΔFosB protein increase (≈ 3‑fold vs.~control) and the highest number of ΔFosB‑bound enhancers, consistent with the ``long‑lasting'' ΔFosB signature reported in the literature (Section 2).\\ \item \textbf{Opioids (heroin)} yielded the strongest NF‑κB protein elevation and the greatest number of NF‑κB gain‑of‑binding peaks, aligning with opioid‑induced TLR4/NF‑κB activation described previously.\\ \item \textbf{Alcohol} uniquely enhanced p‑CREB protein modestly but generated the greatest number of p‑CREB binding events, reflecting the complex temporal dynamics of CREB phosphorylation during chronic ethanol exposure. \end{itemize} \hypertarget{exposure-duration}{% \subsubsection{4.5.2 Exposure duration}\label{exposure-duration}} Within each drug cohort, a secondary analysis compared early (first 7 days) versus late (final 7 days) exposure windows (n = 6 per window). ΔFosB protein showed a \textbf{time‑dependent rise}: early cocaine exposure produced a 1.8‑fold increase, whereas late exposure reached 3.2‑fold (interaction \emph{F}₍₁,₁₀₎ = 9.6, \emph{p} = 0.012). Conversely, NF‑κB binding peaked at the early stage of heroin self‑administration and plateaued thereafter, suggesting an acute inflammatory trigger that stabilizes over time. \hypertarget{sex}{% \subsubsection{4.5.3 Sex}\label{sex}} Across all drugs, females displayed \textbf{significantly higher ΔFosB protein and binding} after cocaine (Δ = +34 \%, \emph{p} = 0.011) and \textbf{greater NF‑κB protein} after heroin (Δ = +16 \%, \emph{p} = 0.043). No sex differences were observed for ethanol‑induced p‑CREB protein, but females showed a modestly higher p‑CREB binding intensity (Δ = +12 \%, \emph{p} = 0.037). These findings substantiate the sex‑specific TF modulation highlighted in Section 2. \hypertarget{summary-of-quantitative-outcomes}{% \subsection{4.6 Summary of quantitative outcomes}\label{summary-of-quantitative-outcomes}} \begin{itemize} \tightlist \item \textbf{ΔFosB}: strongest induction in cocaine‑exposed females (protein ≈ 3‑fold, transcript ≈ +1.1 log₂FC, \textgreater{} 1,800 new binding sites).\\ \item \textbf{p‑CREB}: moderate protein rise across drugs, most pronounced binding expansion after ethanol (≈ 1,400 new peaks).\\ \item \textbf{NF‑κB p65}: dominant response to heroin and ethanol, with \textgreater{} 1,700 new binding sites and significant protein elevation in both sexes, especially females after heroin. \end{itemize} Collectively, the data provide a high‑resolution, sex‑aware atlas of TF dysregulation in the NAc that bridges molecular alterations to drug‑specific behavioral phenotypes. (All figures referenced are located in the Results section: Fig. 4A-4F). \hypertarget{discussion}{% \section{5. Discussion}\label{discussion}} \hypertarget{linking-transcriptionfactor-remodeling-to-synaptic-plasticity}{% \subsection{5.1. Linking Transcription‑Factor Remodeling to Synaptic Plasticity}\label{linking-transcriptionfactor-remodeling-to-synaptic-plasticity}} The multi‑omics atlas generated in this study reveals a coherent picture in which drug‑class‑specific shifts in transcription‑factor (TF) abundance and DNA‑binding activity converge on distinct synaptic‑remodeling programs within the nucleus accumbens (NAc). \begin{itemize} \item \textbf{ΔFosB as the principal driver of cocaine‑induced structural plasticity.} The \textasciitilde3‑fold elevation of ΔFosB protein in females (and a 2‑fold increase in males) after chronic cocaine, together with the emergence of \textgreater1,800 novel ΔFosB‑bound loci, maps directly onto promoters and enhancers of canonical plasticity genes such as \emph{Arc}, \emph{Bdnf}, and \emph{Grin2b}. Gene‑ontology enrichment of ΔFosB‑occupied regions highlights ``regulation of synaptic transmission'' and ``actin cytoskeleton organization,'' mirroring the well‑documented spine‑densification observed after repeated psychostimulant exposure. The latent factor analysis (Factor 1) further ties the magnitude of ΔFosB binding to the escalation of cocaine intake (r = 0.71), supporting a causal chain: ΔFosB accumulation → transcription of plasticity effectors → reinforcement‑driven behavioral escalation. \item \textbf{NF‑κB as the nexus of heroin‑related neuroinflammation and circuit remodeling.} Heroin self‑administration produced the strongest NF‑κB p65 protein increase (≈12 fmol mg⁻¹ in females) and the greatest number of new NF‑κB peaks (≈1,934). These peaks are enriched for inflammatory mediators (\emph{Il1b}, \emph{Tnf}) and for genes implicated in extracellular‑matrix remodeling (\emph{Mmp9}, \emph{Timp1}). The association of NF‑κB‑driven factor (Factor 2) with withdrawal‑induced hyperalgesia (r = 0.58) suggests that drug‑evoked neuroimmune signaling may remodel synaptic connectivity in a manner that underlies negative‑reinforcement driving continued use. \item \textbf{p‑CREB as a modulator of ethanol‑related homeostatic adaptation.} Although absolute p‑CREB protein changes were modest, ethanol exposure generated the largest expansion of p‑CREB binding sites (≈1,421 new peaks). These sites are concentrated at immediate‑early gene loci (\emph{c‑Fos}, \emph{Egr1}) and at genes governing GABAergic transmission, consistent with ethanol's known impact on inhibitory tone. The inverse correlation between p‑CREB‑driven Factor 3 and locomotor sensitization (r = ‑0.46) aligns with a model in which CREB‑mediated transcription buffers excessive excitatory drive during chronic alcohol exposure. \end{itemize} Collectively, the data support a \textbf{drug‑class‑specific TF‑to‑gene‑to‑synapse axis}: ΔFosB → excitatory plasticity (cocaine), NF‑κB → neuroimmune‑mediated remodeling (heroin), p‑CREB → homeostatic inhibitory adaptation (ethanol). The sex‑dependent amplification of ΔFosB and NF‑κB signals further refines this model, offering a mechanistic substrate for the heightened vulnerability observed in females in pre‑clinical addiction studies. \hypertarget{concordance-and-divergence-with-prior-reports}{% \subsection{5.2. Concordance and Divergence with Prior Reports}\label{concordance-and-divergence-with-prior-reports}} Our findings largely corroborate the canonical view presented in the literature review (Section 2): \begin{longtable}[]{@{}lll@{}} \toprule \begin{minipage}[b]{0.31\columnwidth}\raggedright Prior Observation\strut \end{minipage} & \begin{minipage}[b]{0.36\columnwidth}\raggedright Current Confirmation\strut \end{minipage} & \begin{minipage}[b]{0.24\columnwidth}\raggedright Novel Insight\strut \end{minipage}\tabularnewline \midrule \endhead \begin{minipage}[t]{0.31\columnwidth}\raggedright \textbf{ΔFosB accumulation after repeated cocaine} (Robinson \& Kolb, 1999)\strut \end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright Replicated; quantitative proteomics shows a 3‑fold increase, with sex‑specific amplification.\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright First genome‑wide mapping of ΔFosB binding in D1‑ vs.~D2‑MSNs, revealing preferential enrichment at D1‑MSN enhancers.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.31\columnwidth}\raggedright \textbf{Transient p‑CREB rise with acute psychostimulant exposure}\strut \end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright Observed moderate elevation across all drugs; ethanol uniquely expands p‑CREB binding.\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright Demonstrates that chronic ethanol, rather than cocaine, drives sustained CREB‑dependent transcriptional remodeling.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.31\columnwidth}\raggedright \textbf{NF‑κB activation by opioid‑induced TLR4 signaling} (Hutchinson et al., 2012)\strut \end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright Confirmed strong NF‑κB p65 protein increase and binding to inflammatory gene loci after heroin.\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright Extends the paradigm to show sex‑biased NF‑κB amplification and its linkage to withdrawal hyperalgesia.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.31\columnwidth}\raggedright \textbf{Sex differences in TF regulation}\strut \end{minipage} & \begin{minipage}[t]{0.36\columnwidth}\raggedright Replicated: females exhibit larger ΔFosB and NF‑κB responses.\strut \end{minipage} & \begin{minipage}[t]{0.24\columnwidth}\raggedright Provides absolute concentration values and demonstrates that sex differences are not merely transcriptional but also epigenomic (binding‑site expansion).\strut \end{minipage}\tabularnewline \bottomrule \end{longtable} Where divergence appears is in the \textbf{temporal dynamics} of NF‑κB. Earlier work suggested a relatively late, withdrawal‑linked NF‑κB activation, whereas our time‑point (24 h post‑final session) captures an early surge that plateaus, implying that NF‑κB may be engaged both during intoxication and withdrawal phases. This nuance underscores the importance of longitudinal sampling, a methodological advance highlighted in Section 3. \hypertarget{potential-confounds-and-methodological-limitations}{% \subsection{5.3. Potential Confounds and Methodological Limitations}\label{potential-confounds-and-methodological-limitations}} \begin{enumerate} \def\labelenumi{\arabic{enumi}.} \item \textbf{Single post‑exposure time point.} Although the 24‑h window captures a mixture of acute and early withdrawal states, it cannot fully resolve the biphasic kinetics of TF activation (e.g., early NF‑κB surge vs.~late ΔFosB accumulation). Future longitudinal profiling (see Section 7) will be required to map the full trajectory. \item \textbf{Bulk NAc dissection with partial cell‑type resolution.} While fluorescence‑activated nuclei sorting provided D1/D2 MSN separation for a subset of samples, glial and interneuron contributions to TF dynamics remain under‑characterized. This may partially explain residual variance in the MOFA+ latent factors. \item \textbf{Potential influence of stress from self‑administration procedures.} Operant conditioning and catheter implantation can activate hypothalamic‑pituitary‑adrenal (HPA) pathways, which themselves modulate CREB and NF‑κB activity. Control groups underwent identical surgical and handling protocols, mitigating but not eliminating this confound. \item \textbf{Sex hormone cycle not synchronized.} Female mice were not estrous‑stage matched, which could introduce variability in TF levels, especially for ΔFosB and CREB that are known to be hormone‑sensitive. Nonetheless, the observed sex effects persisted despite this variability, suggesting robust biological differences. \item \textbf{Protein quantification reliance on calibrated Western blots.} Although absolute femtomole concentrations were validated by parallel PRM proteomics, low‑abundance isoforms (e.g., ΔFosB splice variants) may be under‑detected. Future use of targeted mass‑spectrometry panels could improve sensitivity. \end{enumerate} \hypertarget{mechanistic-pathways-connecting-tf-alterations-to-addiction-phenotypes}{% \subsection{5.4. Mechanistic Pathways Connecting TF Alterations to Addiction Phenotypes}\label{mechanistic-pathways-connecting-tf-alterations-to-addiction-phenotypes}} \textbf{ΔFosB → Synaptic Strengthening.} ΔFosB's recruitment to \emph{Bdnf} and \emph{Grin2b} enhancers likely enhances NMDA‑receptor‑mediated calcium influx, promoting long‑term potentiation (LTP) at D1‑MSN synapses. This mechanistic link aligns with the observed escalation of cocaine intake (Factor 1 correlation) and with prior electrophysiological data showing increased AMPA/NMDA ratios after chronic cocaine. \textbf{NF‑κB → Neuroimmune‑Mediated Plasticity.} NF‑κB‑driven transcription of \emph{Il1b} and \emph{Tnf} can activate microglial signaling cascades that remodel extracellular matrix proteins (e.g., MMP‑9). Such remodeling may alter spine morphology and reduce inhibitory control, contributing to the heightened withdrawal‑induced hyperalgesia and compulsive seeking observed in heroin‑exposed mice (Factor 2). \textbf{p‑CREB → Homeostatic Counter‑Regulation.} p‑CREB's enrichment at GABA‑synthetic enzyme genes (\emph{Gad1}, \emph{Gad2}) and at \emph{Egr1} suggests a compensatory up‑regulation of inhibitory tone during chronic ethanol exposure. The negative association with locomotor sensitization (Factor 3) supports a model where CREB‑mediated transcription dampens excessive excitatory drive, thereby limiting behavioral sensitization. \textbf{Sex‑Specific Modulation.} Estrogen receptor signaling can potentiate ΔFosB stability (via reduced ubiquitination) and amplify NF‑κB nuclear translocation, providing a molecular basis for the observed female‑biased TF amplification. This intersection of hormonal and TF pathways may underlie the heightened addiction vulnerability reported in epidemiological studies. \hypertarget{implications-for-therapeutic-targeting}{% \subsection{5.5. Implications for Therapeutic Targeting}\label{implications-for-therapeutic-targeting}} The drug‑class‑specific TF signatures identified here suggest \textbf{precision‑targeted interventions}: \begin{itemize} \tightlist \item \textbf{ΔFosB antagonism} (e.g., viral delivery of dominant‑negative ΔFosB or CRISPRi) could attenuate cocaine‑driven synaptic strengthening without broadly suppressing CREB‑mediated neuroprotection.\\ \item \textbf{NF‑κB pathway modulators} (selective IκB kinase inhibitors) may mitigate heroin‑induced neuroinflammation and withdrawal hyperalgesia, especially in females where the response is amplified.\\ \item \textbf{CREB activators} (phosphodiesterase‑4 inhibitors) might enhance the homeostatic buffering capacity during chronic alcohol use, reducing sensitization and relapse risk. \end{itemize} Importantly, the absolute quantification of TF proteins provides a translational benchmark for drug development: candidate molecules can be screened for their ability to normalize TF concentrations to the range observed in control animals. \hypertarget{summary}{% \subsection{5.6. Summary}\label{summary}} The present discussion integrates high‑resolution transcription‑factor profiling with behavioral phenotyping to elucidate how ΔFosB, p‑CREB, and NF‑κB orchestrate drug‑specific synaptic remodeling in the NAc. By confirming and extending prior literature, addressing methodological caveats, and outlining mechanistic pathways, we lay a foundation for TF‑directed therapeutic strategies and set the stage for the longitudinal and cell‑type‑specific investigations proposed in Section 7. \hypertarget{conclusion}{% \section{6. Conclusion}\label{conclusion}} \hypertarget{summary-of-the-transcriptionfactor-landscape-in-the-nac}{% \subsection{6.1 Summary of the transcription‑factor landscape in the NAc}\label{summary-of-the-transcriptionfactor-landscape-in-the-nac}} Across cocaine, heroin, and ethanol self‑administration, addiction produced a \textbf{robust, drug‑class‑specific remodeling of transcription‑factor (TF) abundance, DNA‑binding activity, and downstream gene networks} in the nucleus accumbens (NAc). \begin{itemize} \tightlist \item \textbf{ΔFosB} emerged as the dominant TF after chronic cocaine exposure, showing the largest protein accumulation (≈3‑fold increase, especially in females) and \textgreater1,800 novel binding sites that drive excitatory‑synaptic genes (\emph{Arc, Bdnf, Grin2b}).\\ \item \textbf{NF‑κB p65} was most strongly induced by heroin, with a \textgreater2‑fold rise in protein concentration in females and \textasciitilde1,934 new peaks targeting inflammatory and extracellular‑matrix genes (\emph{Il1b, Tnf, Mmp9}).\\ \item \textbf{p‑CREB} displayed the greatest binding expansion after ethanol (≈1,421 new peaks) despite modest protein changes, enriching CRE motifs in immediate‑early and GABAergic genes. \end{itemize} Sex‑specific amplification was evident: females exhibited \textasciitilde34 \% higher ΔFosB after cocaine and \textasciitilde16 \% higher NF‑κB after heroin, underscoring hormonal modulation of TF stability and nuclear translocation. Multi‑omics integration linked each TF to a distinct behavioral phenotype (ΔFosB ↔ cocaine intake escalation; NF‑κB ↔ heroin withdrawal hyperalgesia; p‑CREB ↔ reduced ethanol‑induced locomotor sensitization). Collectively, these data confirm that \textbf{addiction does not merely alter a handful of candidate TFs but reshapes the entire TF regulatory architecture of the NAc in a drug‑ and sex‑dependent manner}. \hypertarget{therapeutic-implications}{% \subsection{6.2 Therapeutic implications}\label{therapeutic-implications}} The quantitative, genome‑wide TF atlas generated here points to \textbf{TF‑centric intervention strategies} that could normalize drug‑specific transcriptional programs while sparing broader NAc function: \begin{longtable}[]{@{}lll@{}} \toprule \begin{minipage}[b]{0.15\columnwidth}\raggedright Target TF\strut \end{minipage} & \begin{minipage}[b]{0.34\columnwidth}\raggedright Rationale for modulation\strut \end{minipage} & \begin{minipage}[b]{0.42\columnwidth}\raggedright Potential therapeutic modality\strut \end{minipage}\tabularnewline \midrule \endhead \begin{minipage}[t]{0.15\columnwidth}\raggedright ΔFosB (cocaine)\strut \end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright Drives persistent excitatory plasticity and correlates with intake escalation (r = 0.71).\strut \end{minipage} & \begin{minipage}[t]{0.42\columnwidth}\raggedright Small‑molecule antagonists of ΔFosB dimerization; CRISPR‑i directed to ΔFosB promoters in D1‑MSNs.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.15\columnwidth}\raggedright NF‑κB p65 (heroin)\strut \end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright Mediates neuroimmune activation and withdrawal‑related hyperalgesia (r = 0.58).\strut \end{minipage} & \begin{minipage}[t]{0.42\columnwidth}\raggedright Selective IκB‑mimetic peptides; viral delivery of dominant‑negative p65 in D2‑MSNs.\strut \end{minipage}\tabularnewline \begin{minipage}[t]{0.15\columnwidth}\raggedright p‑CREB (ethanol)\strut \end{minipage} & \begin{minipage}[t]{0.34\columnwidth}\raggedright Enhances homeostatic gene expression that buffers ethanol‑induced sensitization (inverse correlation, r = ‑0.46).\strut \end{minipage} & \begin{minipage}[t]{0.42\columnwidth}\raggedright Pharmacologic CREB activators (e.g., phosphodiesterase‑4 inhibitors) or CRISPR‑a targeting CREB‑responsive enhancers.\strut \end{minipage}\tabularnewline \bottomrule \end{longtable} Because the TF changes are \textbf{cell‑type and sex‑specific}, future therapeutics will likely require \textbf{targeted delivery platforms} (e.g., AAV vectors with D1/D2‑MSN promoters) and \textbf{sex‑aware dosing regimens} to achieve maximal efficacy with minimal off‑target effects. \hypertarget{concluding-remarks}{% \subsection{6.3 Concluding remarks}\label{concluding-remarks}} The present study provides the first comprehensive, high‑resolution map of how chronic exposure to distinct drugs of abuse reshapes the transcription‑factor milieu of the NAc. By integrating absolute protein quantification, genome‑wide binding profiles, and behavioral correlations, we demonstrate that \textbf{addiction is fundamentally a transcriptional re‑programming disorder}. These insights lay a solid mechanistic foundation for \textbf{precision‑medicine approaches} that target individual TFs to reverse maladaptive gene networks and ultimately mitigate addictive behaviors. \hypertarget{future-directions}{% \section{7. Future Directions}\label{future-directions}} \hypertarget{longitudinal-multiomics-profiling-of-tf-dynamics}{% \subsection{7.1 Longitudinal Multi‑omics Profiling of TF Dynamics}\label{longitudinal-multiomics-profiling-of-tf-dynamics}} \begin{itemize} \tightlist \item \textbf{Rationale} - Section 4 demonstrated that each drug class produces a distinct TF ``signature'' (ΔFosB for cocaine, NF‑κB for heroin, p‑CREB for ethanol) at a single 24‑h post‑exposure time point. To capture the full trajectory from acute exposure through withdrawal and relapse, repeated sampling is required.\\ \item \textbf{Design} - \begin{enumerate} \def\labelenumi{\arabic{enumi}.} \tightlist \item \textbf{Time‑points}: baseline, 1 h, 24 h, 7 days, 30 days, and after a reinstatement challenge.\\ \item \textbf{Cohorts}: balanced male/female mice for each drug model (cocaine, heroin, ethanol) using the self‑administration paradigms described in Section 3.\\ \item \textbf{Read‑outs}: simultaneous RNA‑seq, ATAC‑seq, and calibrated quantitative proteomics (absolute femtomole concentrations) on bulk NAc and on fluorescence‑activated nuclei sorted D1‑ vs.~D2‑MSNs.\\ \end{enumerate} \item \textbf{Expected outcomes} - Mapping of (i) the onset of ΔFosB accumulation versus NF‑κB nuclear translocation, (ii) sex‑specific temporal windows of TF amplification, and (iii) the persistence of TF‑driven gene networks that predict relapse vulnerability (as suggested by the latent factors in Section 5). \end{itemize} \hypertarget{celltypespecific-functional-manipulations}{% \subsection{7.2 Cell‑type‑Specific Functional Manipulations}\label{celltypespecific-functional-manipulations}} \begin{itemize} \tightlist \item \textbf{Why cell‑type resolution matters} - Section 2 highlighted the methodological gap of bulk tissue analyses; Section 4 showed divergent TF binding in D1‑ vs.~D2‑MSNs is likely hidden.\\ \item \textbf{CRISPR‑a/i platform} - \begin{itemize} \tightlist \item \textbf{CRISPR‑a} (dCas9‑VP64) to up‑regulate ΔFosB, p‑CREB, or NF‑κB target genes selectively in D1‑MSNs or D2‑MSNs using Cre‑dependent AAV vectors in Drd1‑Cre and Drd2‑Cre mice.\\ \item \textbf{CRISPR‑i} (dCas9‑KRAB) to silence the same loci, allowing bidirectional testing of causality.\\ \end{itemize} \item \textbf{Read‑outs} - Behavioral assays (progressive‑ratio, conditioned place preference, withdrawal hyperalgesia) combined with in‑vivo calcium imaging of MSN activity and post‑mortem ChIP‑seq to verify on‑target TF binding changes.\\ \item \textbf{Sex‑specific implementation} - Parallel cohorts will be estrous‑cycle‑monitored to assess hormonal modulation of CRISPR efficacy, addressing the sex differences reported in Sections 4 and 5. \end{itemize} \hypertarget{translational-bridges-to-human-studies}{% \subsection{7.3 Translational Bridges to Human Studies}\label{translational-bridges-to-human-studies}} \begin{itemize} \tightlist \item \textbf{Post‑mortem NAc tissue} - Acquire well‑characterized brain banks (e.g., NIH NeuroBioBank) with documented histories of cocaine, opioid, or alcohol use disorder. Apply the same ChIP‑seq and quantitative proteomics pipelines used in mouse work to validate whether the ΔFosB, NF‑κB, and p‑CREB signatures are conserved in humans.\\ \item \textbf{Peripheral biomarkers} - \begin{itemize} \tightlist \item \textbf{Rationale} - Direct NAc sampling is infeasible in living patients; however, TF‑regulated transcripts (e.g., \emph{ARC}, \emph{IL1B}, \emph{BDNF}) and microRNA signatures can be detected in blood‑derived exosomes.\\ \item \textbf{Approach} - Perform RNA‑seq on circulating exosomal RNA from individuals with active substance use versus matched controls, focusing on the downstream gene sets identified in Section 4. Correlate peripheral expression with clinical severity scores and, where possible, with PET imaging of neuroinflammation (NF‑κB proxy).\\ \end{itemize} \item \textbf{Goal} - Establish a translational pipeline that links the mouse TF atlas to clinically accessible read‑outs, paving the way for precision diagnostics. \end{itemize} \hypertarget{integrative-computational-modeling-and-biomarker-development}{% \subsection{7.4 Integrative Computational Modeling and Biomarker Development}\label{integrative-computational-modeling-and-biomarker-development}} \begin{itemize} \tightlist \item \textbf{Multi‑omics integration} - Extend the MOFA+ framework (Section 5) to incorporate longitudinal data (7.1) and cell‑type‑specific CRISPR perturbations (7.2). Generate predictive models of relapse risk based on TF trajectory patterns.\\ \item \textbf{Machine‑learning classifiers} - Train supervised algorithms (e.g., random forest, elastic‑net logistic regression) on combined transcriptomic, epigenomic, and proteomic features to classify drug class, sex, and stage (acute vs.~withdrawal). Validate classifiers on independent human datasets (post‑mortem and peripheral).\\ \item \textbf{Biomarker panel} - From the most informative features, propose a minimal panel (e.g., ΔFosB protein level, NF‑κB‑regulated cytokine mRNA, p‑CREB‑targeted microRNA) for future clinical assay development. \end{itemize} \hypertarget{clinical-translation-and-therapeutic-trial-design}{% \subsection{7.5 Clinical Translation and Therapeutic Trial Design}\label{clinical-translation-and-therapeutic-trial-design}} \begin{itemize} \tightlist \item \textbf{Target validation} - Use the CRISPR‑a/i data (7.2) to prioritize TFs for pharmacological modulation (e.g., ΔFosB antagonists, NF‑κB inhibitors, CREB activators).\\ \item \textbf{Delivery strategies} - Explore viral vectors with D1/D2‑MSN tropism, nanoparticle‑mediated siRNA, or small‑molecule allosteric modulators that cross the blood‑brain barrier.\\ \item \textbf{Phase I/II trial concepts} - \begin{itemize} \tightlist \item \textbf{Population} - Enroll treatment‑seeking individuals with cocaine use disorder (ΔFosB‑focused), opioid use disorder (NF‑κB‑focused), or alcohol use disorder (CREB‑focused), stratified by sex.\\ \item \textbf{Endpoints} - Primary: change in TF‑driven peripheral biomarker panel; secondary: craving scores, relapse rates, neuroimaging of NAc activity.\\ \end{itemize} \item \textbf{Regulatory considerations} - Leverage the quantitative protein standards established in Section 3 to define pharmacodynamic biomarkers acceptable to FDA/EMA for early‑phase trials. \end{itemize} Collectively, these future directions aim to (i) map the temporal and cell‑type architecture of TF reprogramming, (ii) establish causal links between TF activity and addictive behavior, (iii) translate mouse findings to human biology, and (iv) lay the groundwork for TF‑targeted therapeutics that are both sex‑aware and circuit‑specific. \end{document}